PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS

Protalix BioTherapeutics, Inc.

2 Snunit Street
Science Park PO Box 455
Karmiel 21000
972 4 988 9488

Full Time Employees184

Key Executives

NameTitlePayExercisedYear Born
Dr. Yoseph ShaaltielFounder and Exec. VP R&D372.87kN/A1954
Mr. Yaron NaosSr. VP of Operations298.4kN/A1964
Dr. Einat Brill-AlmonSr. VP of Product Devel.444.95kN/A1960
Mr. Dror BashanPres, CEO & DirectorN/AN/AN/A
Mr. Eyal Rubin M.B.A.SVP, CFO & Corp. Sec.N/AN/A1975
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in ILS.


Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which has completed phase IIa clinical trials for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.

Corporate Governance

Protalix BioTherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.